Xilio Therapeutics, Inc. (XLO)
7.75
+0.07
(+0.91%)
USD |
NASDAQ |
Jun 09, 15:51
Xilio Therapeutics SG&A Expense (Quarterly) : 6.928M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Verastem, Inc. | 22.30M |
| KalVista Pharmaceuticals, Inc. | 48.80M |
| Opus Genetics, Inc. | 5.944M |
| Sensei Biotherapeutics, Inc. | 0.00 |
| ACADIA Pharmaceuticals, Inc. | 171.02M |